another EU approval--now for herceptin plus antihormonal for those w metastatic bc

[Lani]

Herceptin Gets Europe Approval for Combination Breast Cancer Treatment

ZURICH (Reuters) May 03 - Swiss drugmaker Roche Holding AG said on Thursday its Herceptin had been approved in Europe for the treatment of advanced breast cancer in combination with hormonal therapy.

Herceptin (trastuzumab) was approved for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer, Roche said in a statement.

The approval is based on data from an international late stage clinical trial, which showed the addition of Herceptin to hormonal therapy doubled the median progression-free survival time.

Herceptin is already approved in Europe for the treatment of early and metastatic, or advanced, HER2-positive breast cancer.

The new approval means its use can be extended, in combination with hormonal therapy for advanced breast cancer.